Literature DB >> 31944560

Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes.

Wei Zhang1, Chang-Yuan Liu1, Li-Nong Ji2, Ji-Guang Wang1.   

Abstract

We investigated association between blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy (LVH) in patients with hypertension and diabetes. Our study participants were treated patients with both diseases, enrolled in a China nationwide registry. The 773 patients were classified into four groups according to the control status of hypertension (systolic/diastolic blood pressure [BP] ≤140/90 mm Hg) and diabetes (HbA1c <7.0%): both uncontrolled (n = 208), only diabetes (n = 175) or hypertension controlled (n = 172), and both controlled (n = 218). Albuminuria was defined as a urinary albumin-to-creatinine ratio of ≥30 mg/g. LVH was assessed by the electrocardiogram Cornell product method. Antihypertensive therapy was not different between the four groups (P ≥ .48). The use of insulin alone or insulin plus oral antidiabetic agents was significantly higher than those with both diseases controlled (P ≤ .02). Patients with controlled hypertension and diabetes had a significantly (P < .0001) lower prevalence of albuminuria (odds ratio 0.22, 95% confidence interval 0.11-0.43) than those with both diseases uncontrolled. Intensive BP control to <130/80 mm Hg was associated with lower risks of albuminuria in all patients (P = .001) and patients with HbA1c <7.0% (P = .048). Intensive glycemic control to HbA1c <6.5% was also associated with a significantly lower risk of albuminuria in all patients (P = .01), but not those with controlled BP (P = .43). Similar trends were observed for LVH, but statistical significance was not achieved on either intensive control condition (P ≥ .07). In patients with hypertension and diabetes, blood pressure and glucose control were associated with a lower prevalence of albuminuria and LVH, especially when achieving a more stringent target.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  albuminuria; controlled; diabetes mellitus; hypertension; left ventricular hypertrophy; uncontrolled

Mesh:

Substances:

Year:  2020        PMID: 31944560      PMCID: PMC8029792          DOI: 10.1111/jch.13793

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  25 in total

Review 1.  New-onset diabetes and antihypertensive drugs.

Authors:  Giuseppe Mancia; Guido Grassi; Alberto Zanchetti
Journal:  J Hypertens       Date:  2006-01       Impact factor: 4.844

2.  Long-term effects of intensive glucose lowering on cardiovascular outcomes.

Authors:  Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

3.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

4.  Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure.

Authors:  Guanmin Chen; Finlay A McAlister; Robin L Walker; Brenda R Hemmelgarn; Norm R C Campbell
Journal:  Hypertension       Date:  2011-03-14       Impact factor: 10.190

5.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

Authors:  Anushka Patel; S MacMahon; J Chalmers; B Neal; M Woodward; L Billot; S Harrap; N Poulter; M Marre; M Cooper; P Glasziou; D E Grobbee; P Hamet; S Heller; L S Liu; G Mancia; C E Mogensen; C Y Pan; A Rodgers; B Williams
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

6.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  From treatment to organ damage; a 5-year follow-up study of ambulatory blood pressure in essential hypertension. Diversity between development of left ventricular hypertrophy and urinary albumin excretion.

Authors:  Aud-E Stenehjem; Reidar Bjørnerheim; Ingrid Os
Journal:  Blood Press       Date:  2007       Impact factor: 2.835

Review 9.  Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.

Authors:  Sean L Zheng; Alistair J Roddick; Rochan Aghar-Jaffar; Matthew J Shun-Shin; Darrel Francis; Nick Oliver; Karim Meeran
Journal:  JAMA       Date:  2018-04-17       Impact factor: 56.272

10.  Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians: a China registry.

Authors:  Jie Song; Chang-Sheng Sheng; Qi-Fang Huang; Li-Hua Li; Chang-Sheng Ma; Xiao-Hui Guo; Li-Nong Ji; Ji-Guang Wang
Journal:  J Hypertens       Date:  2016-08       Impact factor: 4.844

View more
  5 in total

1.  The Protective Effects of Cryptochlorogenic Acid on β-Cells Function in Diabetes in vivo and vitro via Inhibition of Ferroptosis.

Authors:  Yi Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-08       Impact factor: 3.168

2.  The Effect of TCM Syndrome Type and Western Medicine Detection on Patients with Hypertension and Diabetes Mellitus.

Authors:  Ruqin Chen; Min Zhang; Yanqing Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-22       Impact factor: 2.650

3.  On the need of the simultaneous control of arterial hypertension and diabetes mellitus.

Authors:  Luis M Ruilope; Elena Rodriguez-Sánchez; Gema Ruiz-Hurtado
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-15       Impact factor: 3.738

4.  Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes.

Authors:  Wei Zhang; Chang-Yuan Liu; Li-Nong Ji; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-15       Impact factor: 3.738

5.  Association between dyslipidemia and antihypertensive and antidiabetic treatments in a China multicenter study.

Authors:  Chao-Ying Miao; Xiao-Fei Ye; Wei Zhang; Li-Nong Ji; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-06-06       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.